AdipoGen Life Sciences

anti-LAG-3, mAb (blocking) (11E3) (preservative free)

As low as CHF 470.00

In stock

Only %1 left

AG-20B-0011PF-C100100 µgCHF 470.00

AG-20B-0011PF-C500500 µgCHF 1’880.00

Learn more about Immune Checkpoint LAG-3

Specifications / Handling

More Information
Product Details
Synonyms	Lymphocyte Activation Gene-3; FDC Protein; CD223
Product Type	Monoclonal Antibody
Properties
Clone	11E3
Isotype	Mouse IgG1
Source/Host	Purified from concentrated hybridoma tissue culture supernatant.
Immunogen/Antigen	Recombinant human LAG-3.
Label/Conjugates	Preservative Free
Application	ELISA: (capture) Functional Application: Inhibition Immunocytochemistry Immunohistochemistry: (frozen sections) Immunoprecipitation: (10μg/ml) Western Blot: (5μg/ml)
Crossreactivity	Human Monkey
Specificity	Recognizes human and monkey LAG-3.
Purity	≥95% (SDS-PAGE)
Purity Detail	Protein G-affinity purified.
Endotoxin Content	<0.001EU/μg purified protein or <1EU/mg purified protein (LAL test; Lonza).
Concentration	0.5 mg/ml
Formulation	Liquid. In PBS.
Isotype Negative Control	Mouse IgG1 Isotype Control (preservative free)
Shipping and Handling
Shipping	BLUE ICE
Short Term Storage	+4°C
Long Term Storage	-20°C
Handling Advice	After opening, prepare aliquots and store at -20°C. Avoid freeze/thaw cycles.
Use/Stability	Stable for at least 1 year after receipt when stored at -20°C.
Documents
MSDS	Download PDF
Product Specification Sheet
Datasheet	Download PDF

Scientific Background Information

Product Description

Lymphocyte activation gene 3 (LAG-3; CD223) plays an important role in negatively regulating T cell proliferation, function and homeostasis. It is required for maximal natural and induced regulatory T cell (Treg) function. LAG-3 is closely related to the T cell co-receptor CD4 and binds to MHC class II molecules but with a significantly higher affinity than CD4.

Product-specific References

Cellular expression and tissue distribution of the human LAG-3-encoded protein, an MHC class II ligand: B. Huard, et al.; Immunogenetics 39, 213 (1994)
Characterization of the major histocompatibility complex class II binding site on LAG-3 protein: B. Huard, et al.; PNAS 94, 5744 (1997)
Preferential Th1 profile of T helper cell responses in X-linked (Bruton′s) agammaglobulinemia: A. Amedei, et al.; eur. J. Immunol. 31, 1927 (2001) [PMID: 11433390]
A soluble lymphocyte activation gene-3 (sLAG-3) protein as a prognostic factor in human breast cancer expressing estrogen or progesterone receptors: F. Triebel, et al.; Cancer Lett. 235, 147 (2006)
Clonal regulatory T cells specific for a red blood cell autoantigen in human autoimmune hemolytic anemia: F.J. Ward, et al.; Blood 111, 680 (2008)
A Phase I Pharmacokinetic and Biological Correlative Study of IMP321, a Novel MHC Class II Agonist, in Patients with Advanced Renal Cell Carcinoma: C. Brignone, et al.; Clin. Cancer. Res. 15, 6225 (2009) [PMID: 19755389]
Antibody-mediated depletion of lymphocyte-activation gene-3 (LAG-3(+) )-activated T lymphocytes prevents delayed-type hypersensitivity in non-human primates: A. Poirier, et al.; Clin. Exp. Immunol. 164, 265 (2011) [PMC3087919]
Elevated expression of LAG-3, but not PD-1, is associated with impaired iNKT cytokine production during chronic HIV-1 infection and treatment: J.A. Juno, et al.; Retrovirology 12, 17 (2015) [PMC4332911]
T-cell polarization: Potential serological markers in preterm and term infants: S. Frezza, et al.; Early Human Dev. 101, 69 (2016) [PMID: 27416057]
Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non–Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis: I. Datar, et al.; Clin. Cancer Res. 25, 4663 (2019) [PMC7444693]
Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma: V. Atkinson, et al.; J. Immunother. Cancer 8, e001681 (2020) [PMC7682474]

Call	+41 61 926 6040
Fax	+41 61 926 6049